- Rezistence na hormonální léčbu CRPC a prediktivní faktory léčebné odpovědi2015 | First Faculty of Medicine
- Kastračně rezistentní karcinom prostaty - nové sekvence léčby v klinické praxi: zařazení nových inhibitorů androgenní osy v léčbě CRPC před docetaxel: proPublication without faculty affiliation
- What the results of current studies with enzalutamide say - a commentary on the studies2021 | Publication without faculty affiliation
- Význam hormonálních léčiv v sekvenční léčbě metastazujícího CRPC2015 | Third Faculty of Medicine
- Circulating tumor cells as a biomarker for the patients with castration resistant prostate cancerPublication without faculty affiliation
- Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy2018 | First Faculty of Medicine
- Treatment of advanced prostate cancer2016 | First Faculty of Medicine
- New possibilities in monitoring patients suffering from castration resistant prostate cancer by using circulating tumor cells2013 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Darolutamide in the treatment of metastatic castrate-resistant prostate cancer2022 | First Faculty of Medicine
- Detection and characterisation of circulating tumor cells in patients with castration resistant prostate cancer2012 | First Faculty of Medicine
- Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer2014 | Third Faculty of Medicine
- Hladina prostatického specifického antigenu a detekce cirkulujících nádorových buněk u kastračně rezistentního karcinomu prostatyPublication without faculty affiliation
- Detection and characterization of circulating tumor cells in patients with castration resistant prostate cancerPublication without faculty affiliation
- Detection of circulating tumour cells and their clinical application in patients with bioptically proven prostate cancerPublication without faculty affiliation
- Radium-223 v klinické praxi2020 | First Faculty of Medicine
- The first experience with darolutamid in the treatment of prostate cancer2021 | First Faculty of Medicine
- Prognostic significance of circulating tumor cells in castration resistant prostate cancerPublication without faculty affiliation
- Are circulating tumor cells a future weapon in the fight against castration resistant prostate cancer?Publication without faculty affiliation
- Radium-223 jako účinná součást léčebného schématu u mCRPC2019 | First Faculty of Medicine
- Circulating tumor cells as a source of information about castration-resistant prostate cancer2013 | First Faculty of Medicine
- Circulation tumor cells in castration resistant prostate cancerPublication without faculty affiliation
- Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer2018 | First Faculty of Medicine, Central Library of Charles University
- Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression2017 | First Faculty of Medicine
- Zkušenosti s léčbou abirateronem u pacienta s karcinomem prostaty2020 | First Faculty of Medicine
- Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest(R) System for Detection of Circulating Tumor Cells2016 | First Faculty of Medicine
- Enzalutamide before chemotherapy in the treatment of metastatic castration-resistant prostate2019 | First Faculty of Medicine
- Some observations on number inflection of N1N2 structures in contemporary Portuguese2013 | Faculty of Arts
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine